Acta haematologica · 2026
Inverted U-Shaped Relationship between Pre-Discontinuation Tyrosine Kinase Inhibitor Dose Intensity and Treatment-Free Remission Outcome in Chronic Myeloid Leukemia.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Choi Dae-Ho, Jang Jun Ho, Jung Chul Won
Аннотация
INTRODUCTION: Treatment-free remission (TFR) is an established goal for patients with chronic myeloid leukemia in chronic phase (CML-CP) who achieve sustained deep molecular response (DMR) on tyrosine kinase inhibitor (TKI) therapy. However, the relationship between pre-discontinuation dose intensity (DI) and TFR outcome remains poorly characterized.
METHODS: We retrospectively analyzed 146 patients with CML-CP who attempted TFR at Samsung Medical Center between 2003 and 2025. The DI was defined as the time-weighted average ratio of actual to standard TKI dose during the 2-year period preceding discontinuation. The association between DI and TFR failure was modeled using Cox regression with restricted cubic splines (RCSs) in the DI subcohort (n = 126), using a DI of 1.0 as the reference.
RESULTS: In the full cohort, at median follow-up of 22.3 months, 50 (34.2%) patients experienced molecular relapse. TFR probability was 79.5% at 6 months and 61.9% at 48 months. In the DI subcohort, an unadjusted RCS model suggested a nonlinear, inverted U-shaped pattern, but the overall DI effect was not significant (likelihood ratio, p = 0.101; p for nonlinearity = 0.045). In exploratory post hoc groups, intermediate DI showed the highest TFR failure rate (49.0% vs. 25.0% and 28.6%; p = 0.035). The pattern did not reach significance after adjustment for TKI generation (p for nonlinearity = 0.074).
CONCLUSION: These exploratory findings suggest that the biology underlying DMR maintenance, rather than the absolute pre-discontinuation dose, may influence TFR outcome. Given the modest sample size and post hoc design, this hypothesis-generating observation requires confirmation in independent cohorts.
METHODS: We retrospectively analyzed 146 patients with CML-CP who attempted TFR at Samsung Medical Center between 2003 and 2025. The DI was defined as the time-weighted average ratio of actual to standard TKI dose during the 2-year period preceding discontinuation. The association between DI and TFR failure was modeled using Cox regression with restricted cubic splines (RCSs) in the DI subcohort (n = 126), using a DI of 1.0 as the reference.
RESULTS: In the full cohort, at median follow-up of 22.3 months, 50 (34.2%) patients experienced molecular relapse. TFR probability was 79.5% at 6 months and 61.9% at 48 months. In the DI subcohort, an unadjusted RCS model suggested a nonlinear, inverted U-shaped pattern, but the overall DI effect was not significant (likelihood ratio, p = 0.101; p for nonlinearity = 0.045). In exploratory post hoc groups, intermediate DI showed the highest TFR failure rate (49.0% vs. 25.0% and 28.6%; p = 0.035). The pattern did not reach significance after adjustment for TKI generation (p for nonlinearity = 0.074).
CONCLUSION: These exploratory findings suggest that the biology underlying DMR maintenance, rather than the absolute pre-discontinuation dose, may influence TFR outcome. Given the modest sample size and post hoc design, this hypothesis-generating observation requires confirmation in independent cohorts.